Description Bacterium that causes gastritis, peptic ulcer disease, and gastric cancer
Structure Helicobacter pylori is a Gram-negative, microaerophilic, spiral-shaped bacterium belonging to the family Helicobacteraceae. The organism is uniquely adapted to colonize the human stomach and is capable of surviving the highly acidic gastric environment through the production of urease, an enzyme that converts urea into ammonia and carbon dioxide, creating a protective alkaline microenvironment. H. pylori possesses multiple flagella that enable motility through the gastric mucus layer and adherence to gastric epithelial cells. The bacterium is one of the most common chronic bacterial infections worldwide and is recognized as a major cause of chronic gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma.
Diagnosis The diagnosis of Helicobacter pylori infection can be performed using invasive and non-invasive methods. Non-invasive tests include urea breath tests, stool antigen assays, and serological detection of H. pylori-specific antibodies. The urea breath test and stool antigen assays are highly sensitive and specific and are commonly used for both diagnosis and confirmation of eradication following treatment. Invasive diagnostic methods involve upper gastrointestinal endoscopy with gastric biopsy for histological examination, rapid urease testing, culture, or molecular detection by polymerase chain reaction (PCR). Serological assays, including ELISA-based methods, are useful for epidemiological studies and assessment of previous exposure but may not reliably distinguish active from past infection.
Symptoms Helicobacter pylori infection is often acquired during childhood and may persist for life if untreated. Many infected individuals remain asymptomatic; however, chronic infection can lead to inflammation of the gastric mucosa and the development of gastrointestinal disease. Common symptoms include upper abdominal pain or discomfort, nausea, bloating, early satiety, excessive belching, and indigestion. In patients with peptic ulcer disease, symptoms may include burning epigastric pain, gastrointestinal bleeding, vomiting, or anemia. Long-term infection increases the risk of gastric atrophy, intestinal metaplasia, gastric adenocarcinoma, and MALT lymphoma. Eradication of H. pylori significantly reduces the risk of ulcer recurrence and certain gastric malignancies.
Data
FAQ & Publications
Frequently Asked Questions
What is the primary application of the Helicobacter pylori IgA Control Serum BC118A?
The Helicobacter pylori IgA Control Serum BC118A is primarily used as a control serum in ELISA assays, specifically designed for indirect and quantitative detection of Helicobacter pylori reactive IgA antibodies.
How should the Helicobacter pylori IgA Control Serum BC118A be stored to maintain its stability?
The Helicobacter pylori IgA Control Serum BC118A should be stored at 2-8°C to ensure proper preservation and stability of the product.
Publications
pmid
title
authors
citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Reviews
There are no reviews yet.